Terray Therapeutics uses AI and high-tech labs for rapid drug discovery, generating 50 terabytes of data daily. Co-founded by Jacob and Eli Berlin, the company focuses on small-molecule drugs. Their AI model accelerates development, with partnerships including Bristol Myers Squibb. Aiming to improve clinical success rates, Terray expects to begin trials by 2026.